Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443511 | 0.70 | — | — | |
| SCHEMBL17527498 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL30153676 | 0.67 | — | — | |
| SCHEMBL168677 | 0.65 | — | — | |
| SCHEMBL27815530 | 0.64 | — | — | |
| SCHEMBL7604374 | 0.62 | KDM4E (0.33) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL4552679 | 0.62 | KDM4E (0.30) | KDM4EALDH1A1HPGD | |
| SCHEMBL17261368 | 0.62 | KDM4E (0.30) | KDM4EALDH1A1HPGD | |
| SCHEMBL1382217 | 0.62 | — | — | |
| SCHEMBL1638013 | 0.62 | KDM4E (0.30) | KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935824-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-05-03 | — | — | US | claimed |
| US-20230147616-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115960139-A | Organic electroluminescent material and device | 环球展览公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8148089-B2 | Alpha-synuclein kinase | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2012-04-03 | — | — | US | disclosed |
| EP-2431370-A1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | QIU, QIYU | 2004-05-06 | — | — | US | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1395585-A1 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-10 | — | — | EP | disclosed |
| EP-1366027-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | McGILL UNIVERSITY (CA) | 2003-12-03 | — | — | EP | disclosed |
| US-20030114458-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002096908-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002068396-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | MCGILL UNIVERSITY (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114458-A1 | Antibacterial agents | MRPL21, RPS6, RPS6KA1 | KDM4E 2624/4885ALDH1A1 657/4885POLB 2454/4885 |
| US-20230147616-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | KDM4E 2824/4885ALDH1A1 1283/4885POLB 2059/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | KDM4E 2746/4885ALDH1A1 3225/4885POLB 2938/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | KDM4E 3759/4885ALDH1A1 3734/4885POLB 1011/4885 |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | EGFR, PCNA, ERCC2 | KDM4E 4259/4885ALDH1A1 2925/4885POLB 20/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | KDM4E 645/4885ALDH1A1 2109/4885POLB 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.